테낙스 테라퓨틱스(TENX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.91 (+2.69%), 시가총액 $0.33B, 52주 최저~최고 $5.62 ~ $18.27.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North
테낙스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
테낙스 테라퓨틱스의 현재 주가는 $1.91 (+2.69%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
테낙스 테라퓨틱스의 시가총액은 약 $0.33B입니다.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have